Assertio Therapeutics (ASRT) Tops Q2 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. NVDA
7. CRBU
8. HALO
9. BBIO
10. SPY

Go back to Assertio Therapeutics (ASRT) Tops Q2 EPS by 20c

Assertio Reports Second Quarter 2022 Financial Results

August 8, 2022 7:01 AM EDT

Net Product Sales Increase 40% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases to $22.9 million

Raises Full Year Revenue and Non-GAAP Adjusted EBITDA Guidance

LAKE FOREST, Ill., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2022.

Financial Highlights (unaudited):

 Three Months Ended June... More